

Amendments to the Specification:

Please delete the paragraph on page 1, line 24 to page 2, line 8, and replace it with the following paragraph:

IGFBP-4 was first isolated from medium conditioned by human osteosarcoma TE-89 cells (Mohan, Se., et al., Proc. Acad. Sci. USA 86 (1989) 8338-8342). IGFBP-4 is known to exist naturally as a non-glycosylated form with an apparent molecular weight of 24 kDa or in the glycosylated form weighing 28kDa. Recombinant IGFBP-4 was produced by expression in several eukaryotic and prokaryotic systems. Human IGFBP-4 was produced by expression in *E. coli* as a fusion protein with glutathione S-transferase (Honda, Y. et al., J. Clin. Endocrinol. Metab. 81 (1996) 1389-1396) or as a fusion protein with a hexahistidine tag (SEQ ID NO:3) (Qin, X. et al., J. Biol. Chem. 273 (1998) 23509-23516) or by expression in yeast as a ubiquitin fusion protein (Kiefer, M.C., et al., J. Biol. Chem. 267 (1992) 12692-12699). The sequence of human IGFBP-4 (SEQ ID NO:1) is described in detail in the SwissProt Database (<http://www.expasy.ch>) and identified by the Accession No. P22692. The amino acid positions described in the following refer to the sequence of the mature forms of IGFBP-4 (SEQ ID NO:2) (sequence after removal of the signaling peptide starts with amino acid in position 1) or refer to the numbering used in the cited references.

Please insert the Sequence Listing, submitted herewith, after page 32 of the specification.